Wellgistics Shifts to Direct-to-Consumer Drug Sales, Targets 36M GLP-1 and 18M Long-COVID Patients
Wellgistics will shift to direct-to-consumer drug sales via its online pharmacy, extending its EinsteinRx AI platform and deploying blockchain-based PharmacyChain serialization. The company is partnering with NFL Alumni Health, licensing DataVault AI technology, adding a benefits verification tool, and targeting 36M+ GLP-1 users and 18M+ long-COVID patients via Tollo Health.
1. Strategic Shift to Direct-to-Consumer Sales
Wellgistics announced that it will pivot from traditional pharmacy distribution to direct-to-consumer prescription drug sales through its online pharmacy, aiming to capture higher margins and foster closer patient relationships.
2. AI and Blockchain Platform Expansion
The company plans to extend its EinsteinRx AI hub beyond dispensing optimization and deploy its patented PharmacyChain blockchain serialization solution, enabling secure drug data tokenization and comprehensive patient record integration to improve outcomes.
3. Key Partnerships and Patient Targeting
Wellgistics has partnered with NFL Alumni Health for consumer outreach, licensed DataVault AI serialization technology, added a benefits verification tool, and is collaborating with Tollo Health to target over 36 million GLP-1 users and 18 million long-COVID patients.